BioWorld

Sep. 27, 2006

View Archived Issues

Millennium Makes $515M Offer For AnorMED, Tops Genzyme

Millennium Pharmaceuticals Inc. agreed to a $515 million premium purchase of AnorMED Inc., outbidding Genzyme Corp. for the Canadian biopharmaceutical firm and its Phase III cancer drug, Mozobil. (BioWorld Today) Read More

Von Eschenbach: Strengthen FDA To Help Drug Discovery

Read More

Conditional Degron Opens Up Reversible Protein Knockouts

Read More

Arena, Merck Drop Pro-HDL Effort, But Drug's Still Alive

Read More

Immunicon's CellTracks Hits Endpoints In Cancer Study

Read More

Other News To Note

Read More

Clinic Roundup

Read More